Anil Parsram Bidkar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Anil Parsram Bidkar has a total of 154 co-authors. Here are the top co-authors by number of shared publications:
- Robert Richard Flavell
Department of Radiology and Biomedical Imaging University of California, San Francisco San Francisco California USA
383 shared publications - David Meybin Wilson
Department of Radiology and Biomedical Imaging, University of California, San Francisco, USA
321 shared publications - Henry F. VanBrocklin
Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California
319 shared publications - Youngho Seo
University of California
319 shared publications - Anju Wadhwa
University of California, San Francisco 1 Department of Radiology and Biomedical Imaging San Francisco, California
317 shared publications - Kondapa Naidu Bobba
University of California, San Francisco 1 Department of Radiology and Biomedical Imaging San Francisco, California
317 shared publications
Latest Publications
- Open Access
- 5 October 2026
- Published by Springer Nature in Nature Biomedical Engineering
- p. 1-18
Selective PET imaging of bacterial infection using a glycosylated 18F-fluorodeoxyglucose-derived tracer
Distinguishing bacterial infection from non-infectious inflammation remains challenging because most clinical imaging detects the host inflammatory response rather than the bacteria themselves. The widely used glucose analogue 18 F-fluorodeoxyglucose accumulates in metabolically active tissues, including immune cells, resulting in high background signals and limited specificity. Here we report a positron emission tomography tracer that directly targets bacterial metabolism by exploiting the phosphotransferase system, a carbohydrate transport pathway absent in mammalian cells. O -glycosylation of 18 F-fluorodeoxyglucose generated a library of alkyl glucosides in a single step (33–92% yield), enabling rapid screening for bacterial uptake. In vitro studies identified a methanol-derived tracer in which the β-anomer showed selective incorporation into Staphylococcus species via the glucose-specific phosphotransferase transporter. This positron emission tomography tracer was stable in human serum and showed minimal uptake in mammalian cells and uninfected tissues. In murine models, it detected sites of live gram-positive infection with more than sixfold higher signal than non-infected tissue, without accumulation in aseptic inflammation, and enabled monitoring of response to antibiotic therapy.
- 5 October 2026
- Published by Springer Nature in Nature Biomedical Engineering
- p. 1-18
Open AccessSelective PET imaging of bacterial infection using a glycosylated 18F-fluorodeoxyglucose-derived tracer
Distinguishing bacterial infection from non-infectious inflammation remains challenging because most clinical imaging detects the host inflammatory response rather than the bacteria themselves. The widely used glucose analogue 18 F-fluorodeoxyglucose accumulates in metabolically active tissues, including immune cells, resulting in high background signals and limited specificity. Here we report a positron emission tomography tracer that directly targets bacterial metabolism by exploiting the phosphotransferase system, a carbohydrate transport pathway absent in mammalian cells. O -glycosylation of 18 F-fluorodeoxyglucose generated a library of alkyl glucosides in a single step (33–92% yield), enabling rapid screening for bacterial uptake. In vitro studies identified a methanol-derived tracer in which the β-anomer showed selective incorporation into Staphylococcus species via the glucose-specific phosphotransferase transporter. This positron emission tomography tracer was stable in human serum and showed minimal uptake in mammalian cells and uninfected tissues. In murine models, it detected sites of live gram-positive infection with more than sixfold higher signal than non-infected tissue, without accumulation in aseptic inflammation, and enabled monitoring of response to antibiotic therapy.
- Open Access
In vivo Quantitative Tomography of 225 Ac Daughters in a Prostate Cancer Mouse Model with a Compton Camera
Targeted alpha therapy with 225 Ac is a promising modality for cancer treatment, as shown in recent preclinical and clinical studies. Preclinical imaging of 225 Ac is essential to fully understand the biokinetics of developmental 225 Ac radiopharmaceuticals. Although single photon emission computed tomography (SPECT) is typically used to achieve this in vivo, conventional preclinical scanners struggle to provide high contrast and accurate quantification for 225 Ac imaging due to the very low injected activities (below 1 kBq / g), the unfavorable gamma-ray branching ratios (225 Ac daughters in live mice at 18.5 kBq (0.5 µ Ci) injected activities. Three mice bearing 22Rv1 prostate cancer subcutaneous xenografts were scanned in a single bed position for 30 minutes following intravenous administration of 18.5 kBq of the Anti-CD46 225 Ac-Macropa-PEG 4 -YS5 conjugate. We successfully visualized the in vivo biodistributions of the 225 Ac daughters 221 Fr and 213 Bi, distinguishing between the tumor xenograft and the central organs. Quantification of the tumor uptake from the images revealed an activity as low as 1.1 kBq. In vivo activity quantification computed from the images was compared to ex vivo biodistribution measurements using a gamma counter after harvesting the tissue, showing strong agreement.
Open AccessIn vivo Quantitative Tomography of 225 Ac Daughters in a Prostate Cancer Mouse Model with a Compton Camera
Targeted alpha therapy with 225 Ac is a promising modality for cancer treatment, as shown in recent preclinical and clinical studies. Preclinical imaging of 225 Ac is essential to fully understand the biokinetics of developmental 225 Ac radiopharmaceuticals. Although single photon emission computed tomography (SPECT) is typically used to achieve this in vivo, conventional preclinical scanners struggle to provide high contrast and accurate quantification for 225 Ac imaging due to the very low injected activities (below 1 kBq / g), the unfavorable gamma-ray branching ratios (225 Ac daughters in live mice at 18.5 kBq (0.5 µ Ci) injected activities. Three mice bearing 22Rv1 prostate cancer subcutaneous xenografts were scanned in a single bed position for 30 minutes following intravenous administration of 18.5 kBq of the Anti-CD46 225 Ac-Macropa-PEG 4 -YS5 conjugate. We successfully visualized the in vivo biodistributions of the 225 Ac daughters 221 Fr and 213 Bi, distinguishing between the tumor xenograft and the central organs. Quantification of the tumor uptake from the images revealed an activity as low as 1.1 kBq. In vivo activity quantification computed from the images was compared to ex vivo biodistribution measurements using a gamma counter after harvesting the tissue, showing strong agreement.
- Open Access
- 1 August 2026
- Published by American Chemical Society (ACS) in ACS Central Science
- Vol. 12 (8) , 1258
Correction to “Detecting Bacteria in Their Mammalian Hosts Using Metabolism-Targeted [13C]CO2 Breath Testing”
- 1 August 2026
- Published by American Chemical Society (ACS) in ACS Central Science
- Vol. 12 (8) , 1258
Open AccessCorrection to “Detecting Bacteria in Their Mammalian Hosts Using Metabolism-Targeted [13C]CO2 Breath Testing”
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S14 from PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Table S14. Comparison of influx and efflux rates of [89Zr]PEG-DFB4 and [89Zr]PEG-DFB1-TLZ3 conjugates in different subcutaneous tumor models (n = 4, mean ± SD). *Prior published data.6
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S14 from PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Table S14. Comparison of influx and efflux rates of [89Zr]PEG-DFB4 and [89Zr]PEG-DFB1-TLZ3 conjugates in different subcutaneous tumor models (n = 4, mean ± SD). *Prior published data.6
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S33 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
Figure S33. Body weight measurements for the MM.1S disseminated tumor-bearing animals treated with [225Ac]Macropa-PEG4-YS5-MMAE.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S33 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
Figure S33. Body weight measurements for the MM.1S disseminated tumor-bearing animals treated with [225Ac]Macropa-PEG4-YS5-MMAE.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Figure S10. Organ biodistribution presented in (left) %ID/g, and (right) %ID/organ for 89Zr labeled nanocarriers in nude mice bearing LTL-545 patient derived xenograft (PDX) of tumors at 96 h postinjection. (n = 4, mean ± SD)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Figure S10. Organ biodistribution presented in (left) %ID/g, and (right) %ID/organ for 89Zr labeled nanocarriers in nude mice bearing LTL-545 patient derived xenograft (PDX) of tumors at 96 h postinjection. (n = 4, mean ± SD)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Figure S2. Pilot PET/CT studies in prostate, pancreatic, and colorectal cancer models to measure the enhanced permeability retention effect using [89Zr]PEG-DFB1-TLZ3.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Figure S2. Pilot PET/CT studies in prostate, pancreatic, and colorectal cancer models to measure the enhanced permeability retention effect using [89Zr]PEG-DFB1-TLZ3.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S34 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
Figure S34. Body weight measurements for the RPMI disseminated tumor bearing animals treated with [225Ac]Macropa-PEG4-YS5-MMAE.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S34 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
Figure S34. Body weight measurements for the RPMI disseminated tumor bearing animals treated with [225Ac]Macropa-PEG4-YS5-MMAE.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S13 from PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Table S13. Organ biodistribution analysis data in %ID/Organ tissue for 89Zr labeled nanocarriers at 96 h in mice model bearing LTL-610 subcutaneous tumors. (n = 4)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S13 from PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Table S13. Organ biodistribution analysis data in %ID/Organ tissue for 89Zr labeled nanocarriers at 96 h in mice model bearing LTL-610 subcutaneous tumors. (n = 4)